Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications

Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL-CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL-CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL-CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first-line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim.

Authors

Institutions

Publication Details

Journal
Hematological Oncology
Published
2024-09-01
DOI
https://doi.org/10.1002/hon.3311
Citations
1
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.45
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications

Ester Pungolino, Cinzia Sissa, Michela Anghilieri, Alessandra Iurlo et al.
1 citations
Hematological Oncology
Chronic Myeloid Leukemia Treatments
0.45
article

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications

Ester Pungolino, Cinzia Sissa, Michela Anghilieri, Alessandra Iurlo, Nicola Polverelli, Angelo Gardellini, Maria Cristina Carraro, Michele Ercolanoni, Roberto Palazzolo, Chiara Elena, Carlo Gambacorti‐Passerini, Paolo Corradini, Nicola Orofino, Rossella Calori, Tamara Intermesoli, Fabio Giglio, Marta Ubezio, Margherita Maffioli, Cristina Fiamenghi, Francesca Lunghi, V. Bertolli, Maria Cristina Pasquini, Mariella D’Adda
article en
1 citations

Abstract

Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL-CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL-CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL-CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first-line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim.

Hematological OncologyVol. 42(5)
Vita-Salute San Raffaele University (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), ASST Melegnano e della Martesana (IT), Ospedale di Circolo di Busto Arsizio (IT), Agenzia Regionale per la Protezione dell'ambiente ligure (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Policlinico San Matteo Fondazione (IT), Azienda Ospedaliera di Desio e Vimercate (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Socio Sanitaria Territoriale della Valtellina e Alto Lario (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), ASST Fatebenefratelli Sacco (IT), Ospedale Valduce (IT), IRCCS Humanitas Research Hospital (IT), Istituti Ospitalieri di Cremona (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Aziende Socio Sanitarie Territoriale Ovest Milanese, Aziende Socio Sanitarie Territoriali di Lecco, Aziende Socio Sanitarie Territoriale dei Sette Laghi, Azienda Socio Sanitaria Territoriale di Cremona, European Institute of Oncology (IT), University of Milano-Bicocca (IT)
Good health and well-being
Openalex Percentile: Top 33%
Chronic Myeloid Leukemia Treatments
0.45
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.